The global hepatitis B infection market is driven by the increasing prevalence of chronic hepatitis B cases, rising awareness about vaccination, and advancements in antiviral therapies. With millions affected worldwide, particularly in regions such as Asia-Pacific and Africa, demand for effective treatment and prevention strategies continues to grow. Key market players, including Gilead Sciences, GSK, Dynavax Technologies, Roche, and Bristol-Myers Squibb, are leading innovation in antiviral drugs, vaccines, and immunotherapies. The market is witnessing a shift towards combination therapies and functional cure research, with companies investing in next-generation treatments targeting HBV RNA and immune modulation. Additionally, government initiatives and vaccination programs are boosting market growth, while diagnostic advancements are improving early detection and disease management. Overall, the hepatitis B infection market is poised for steady growth, driven by continuous R&D and increasing global healthcare investments.
Global Hepatitis B Infection Market is valued at USD 12.72 billion in 2024 and is expected to reach USD 19.16 billion by 2032, with a growing CAGR of 5.2% during the forecast period 2025 to 2032.
To know more, visit https://www.databridgemarketresearch.com/reports/global-hepatitis-b-infection-market
Below are the Top Forestry Equipment Companies with a Significant Market Share:
|
Rank |
Company |
Overview |
Product Portfolio |
Sales Geographical Coverage |
Developments |
|
1. |
Gilead Sciences, Inc. |
Gilead Sciences, Inc. is a leading biopharmaceutical company specializing in the research, development, and commercialization of antiviral drugs. The company has played a crucial role in the treatment of hepatitis B with its antiviral therapies, including Vemlidy (tenofovir alafenamide) and Viread (tenofovir disoproxil fumarate). Gilead continues to advance hepatitis B research, aiming to develop a functional cure. The company operates globally, with a strong presence in North America, Europe, and Asia-Pacific. |
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe |
In September 2024, Gilead Sciences and Genesis Therapeutics announced a strategic collaboration to discover and develop novel small molecule therapies using Genesis’ GEMS AI platform. Gilead gained exclusive rights to develop and commercialize products from this partnership. |
|
2. |
GSK plc. |
GSK plc. (formerly GlaxoSmithKline) is a British multinational pharmaceutical and biotechnology company with a strong presence in infectious disease treatment and prevention. The company is a major player in the hepatitis B market through its Engerix-B vaccine, which provides protection against hepatitis B infection. GSK is also involved in research to develop new treatment approaches, leveraging its expertise in immunology and antiviral drug development. |
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe |
In July 2024, GSK and CureVac restructured their collaboration into a new licensing agreement. GSK acquired global rights to mRNA vaccines for influenza and COVID-19, while CureVac received USD 435 million upfront and up to USD 1.15 billion in milestone payments. |
|
3. |
Dynavax Technologies |
Dynavax Technologies Corporation is a biopharmaceutical company specializing in innovative vaccines and immunotherapies. The company's flagship product for hepatitis B is HEPLISAV-B, a recombinant hepatitis B vaccine designed to offer higher and longer-lasting immune protection compared to traditional vaccines. Dynavax continues to expand its vaccine portfolio, aiming to improve immunization strategies worldwide. |
|
U.S., Germany |
In May 2024, Dynavax Technologies announced that the FDA issued a Complete Response Letter regarding its supplemental Biologics License Application for a four-dose HEPLISAV-B® regimen for adults on hemodialysis, citing insufficient data. The approved indication for HEPLISAV-B remains unchanged, while the European Commission approved the regimen in October 2023. |
|
4. |
F. Hoffmann-La Roche Ltd. |
F. Hoffmann-La Roche Ltd., commonly known as Roche, is a Swiss multinational healthcare company known for its expertise in pharmaceuticals and diagnostics. The company has developed Pegasys (peginterferon alfa-2a), a treatment for chronic hepatitis B that stimulates the immune system to control the infection. Roche also focuses on diagnostic innovations, providing advanced testing solutions for hepatitis B detection and monitoring. |
Pegasys (peginterferon α) |
Americas, Africa, Asia and Europe |
In November 2023, Roche introduced Elecsys HBeAg quant, an advanced immunoassay designed to detect and quantify hepatitis B e antigen (HBeAg) in human serum and plasma. This innovation enables both qualitative and quantitative assessment of HBeAg, allowing for more precise diagnosis and monitoring of hepatitis B (HBV). By integrating this test with other laboratory findings and clinical evaluations, healthcare providers can confirm HBV infection, determine its severity, and effectively track treatment progress using a single assay. |
|
5. |
Bristol-Myers Squibb |
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company engaged in the development of innovative medicines for serious diseases, including viral infections. The company’s key contribution to the hepatitis B market includes Baraclude (entecavir), an antiviral drug used to manage chronic hepatitis B infection. BMS continues to explore new therapies to enhance patient outcomes and address unmet medical needs in hepatitis B treatment. |
|
North America, Asia-Pacific, and Europe |
In December 2020, BMS awarded a one-year, $134,000 grant to the Hepatitis B Foundation. The grant aims to address disparities related to HBV-associated liver cancer among high-risk groups in the U.S., including Asian Americans, Pacific Islanders, and African immigrant communities. |
Conclusion
The global hepatitis B infection market is set for sustained growth, driven by rising disease prevalence, advancements in antiviral therapies, and expanding vaccination programs. Leading pharmaceutical companies such as Gilead Sciences, GSK, Dynavax Technologies, Roche, and Bristol-Myers Squibb are at the forefront of innovation, developing more effective treatments and preventive solutions. The market is experiencing a shift towards novel combination therapies and functional cure research, aiming for long-term disease management. In addition, increased government initiatives and improved diagnostic tools are enhancing early detection and treatment accessibility. However, challenges such as high treatment costs and healthcare disparities in low-income regions remain barriers to widespread disease control. Despite these hurdles, ongoing research and strategic investments in the hepatitis B market indicate promising advancements, fostering better patient outcomes and expanding global healthcare access.
